The glucocorticoid receptor (GR) consists of two alternatively spliced isoforms: GRa, which activates gene transcription, and GRb, a dominant-negative receptor. Theoretically, inactivating variants of GRb could result in glucocorticoid hypersensitivity.
R esponses to administration of exogenous glucocorticoids in individual patients can be highly variable; accordingly, therapeutic doses are often titrated upward or downward to achieve desired clinical effects (1) (2) (3) (4) (5) . Intraindividual variability may result from one or a combination of possible factors including alterations in levels and isoforms of the glucocorticoid receptors (GRs), their coactivators and corepressors, metabolic clearance rates, 11b-hydroxysteroid dehydrogenase activity, corticosteroidbinding proteins, and patient compliance (1, 4, (6) (7) (8) (9) (10) . In addition, functional mutations of GRs can influence the actions of exogenous glucocorticoids and hypothalamicpituitary responses to them. Two distinct GRs formed by alternative splicing of the GR gene (NR3C1) have been described: GRa, an activating receptor, and GRb, which is dominant negative (1, 3, (11) (12) (13) (14) (Fig. 1) . To add to the complexity, alternative translation initiation of GR mRNA results in generation of multiple GR variants (15) .
Mutations in the GR can result in either glucocorticoid resistance or hypersensitivity (3, (16) (17) (18) . Several GR mutations are associated with glucocorticoid resistance, including ER22/23EK in exon 2 of GRa and A3669G in GR9b (1, 19, 20) . These mutations are well recognized clinically and associated predominantly with hirsutism, acne, hypokalemia, and hypertension (1, 3, 21) . Mechanistically, GR resistance diminishes hypothalamic-pituitary negative feedback by cortisol and results in ACTH elevations that can stimulate adrenal mineralocorticoids and androgens (1, 21) . Glucocorticoid hypersensitivity has also been reported to occur as a result of GRa mutations. The best characterized are two relatively common variants: N363S (6% population prevalence) and Bcl1 (14% prevalence) (2, 3, 5, (22) (23) (24) (25) . No previous reports describe inactivating mutations of GRb that theoretically could abrogate the dominant-negative effects of GRb and result in hypersensitivity.
In this article, we report a patient with two GRb and one GRa activation variants that were associated with hypersensitivity to glucocorticoids. The findings supporting hypersensitivity in this prismatic case include (1) consistently low morning cortisol levels in the face of normal responses to provocative tests of both adrenal and hypothalamicpituitary function; (2) exaggerated suppression of morning cortisol in response to ultra-low-dose dexamethasone; (3) development of cushingoid features during subreplacement doses of glucocorticoid; (4) hypersensitivity of osteosarcoma cells transfected with mutated GRb genes; and (5) hypersensitivity of GILZ, a candidate glucocorticoidresponsive gene, in the patient's cells.
As a practical means of assessing the degree of clinical manifestations, we devised a classification system describing mild, moderate, and severe hypersensitivity (Fig. 2) . Mild hypersensitivity is manifested by exaggerated responses to low doses of exogenous glucocorticoid, as exemplified by studies in Crohn disease and congenital adrenal hyperplasia (26, 27) or clinical responses to subreplacement doses of glucocorticoid in rheumatoid arthritis (28) . Moderate is characterized by exaggerated suppression of plasma cortisol by exogenous ultra-low-dose dexamethasone as previously published (2, 22) . Severe is associated with consistently low circulating plasma cortisol levels in addition to exaggerated ultra-low-dose dexamethasone suppression and clinical responses to subtherapeutic doses of exogenous glucocorticoid. The patient in this report presented with GRb variants meeting the criteria for severe glucocorticoid hypersensitivity (Fig. 2 ).
Materials and Methods

Hormone assays
Serum cortisol concentration was measured by standard clinical cortisol radioimmunoassays in two separate laboratories (University of Virginia and LabCorp) and plasma ACTH concentration by immunometric assay (29) . To exclude potential problems with sensitivity and specificity of the cortisol radioimmunoassay measurements, two values with serum concentrations of 2.7 and 2.3 mg/dL (SI units, 74 and 63 nmol/L) were reassayed with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay at the Mayo Clinic Laboratories (cortisol, serum) and similar values were detected [3.6 and 2.8 mg/dL; reference range, 7 to 25 mg/dL (SI units, 193 Urinary free cortisol (Cortisol, Free, 24-hour urine) and exogenous urinary steroid levels (Synthetic Glucocorticoid Screen) were measured by LC-MS/MS at the Mayo Clinic Laboratory. Dexamethasone and cortisol levels during the dexamethasone suppression test were measured at the ARUP laboratory (cortisol and dexamethasone using LC-MS/MS) (30) . Salivary cortisol levels were measured by enzyme immunoassay at the Endocrine Research Laboratory at Aurora St. Luke's Medical Center in Milwaukee, Wisconsin (31) . The ultra-low-dose dexamethasone suppression test used the protocol of Huizenga et al. (22) with administration of 0.25 mg of dexamethasone at 11 PM with plasma for cortisol and dexamethasone measured at 8 AM. The values in patients with the Bcl1 and N363S mutations are taken from the Huizenga et al. publication (22) .
Exon sequencing of GRa and GRb
Genomic DNA was isolated from peripheral blood leukocytes using the Qiagen DNeasy Blood and Tissue kit. Genomic DNA was then amplified using DNA primers designed to the coding sequence of GRa, GRb, and the a and b 3 0 UTR. Fragments were sequenced using Sanger sequencing. In addition, PCR-based allelic discrimination was used to identify the most common GR polymorphisms: E22E, R23K, Bcl1, N363S, G3134T, and A3669G as previously described (32) .
Osteosarcoma cell line studies
Methods for constructing three stable cell lines containing (1) GRa alone, (2) GRa and wild-type GRb, and (3) GRa and the two GRb variants GR9b G3134T and GR9b A3669Gwere performed according to the detailed methods described elsewhere (15, 33) and used in the coauthors' laboratory (C.M.J., J.A.C.). The methods sections of two publications from the Cidlowski laboratory detail the sources and reagents used in this study and the methods for the construction and use of plasmids, cell cultures, western blots, immunofluorescent cytoplasmic/nuclear localizations studies, and real-time PCR methodology (15, 33) . Briefly, the general principles were to transfect GRa, GRb wild-type, and the mutant GRb vectors into osteosarcoma cells that contained no endogenous GR. Cells were then grown in selection media containing hygromycin during serial passage in culture medium. Standard methodology was used for western blots, real-time PCR, and immunofluorescence.
cDNA microarray analysis
The Genomics Core Laboratory at the National Institutes of Environmental Health Sciences performed analyses in quadruplicate using methodology as previously described in detail elsewhere (34) . For the cDNA array studies, the three cell lines (i.e., GRa alone, GRa and wild-type GRb, and GRa and two GRb variants) were treated with 100 nM hydrocortisone or vehicle (i.e., ethanol) for 6 hours. RNA was isolated from four replicates of each cell line after treatment and submitted for microarray analysis. The raw data from the microarray analysis were then loaded into the Partek Genomic Suite for analysis. Probes/genes significantly regulated at false discovery rate, step-up P , 0.05 were chosen for further analysis. To analyze the results, Venn diagrams were constructed and Ingenuity Pathway Analysis (IPA) was used to assess the pathways affected. Volcano plots were constructed by the method of Li (35) .
Preparation of patient's lymphocytes
The Ficoll-Paque Premium medium and techniques were used to isolate the lymphocytes from the patient's plasma as described in the manufacturer's directions (GE Healthcare Instructions 28-4039-56-AA). The cells were then subjected to flow cytometry according to our previous methodology (15) .
Statistical analysis
We assessed differences between patient and control salivary cortisol levels by a Student two-sample t test comparing the average of 22 morning cortisol values in the patient with 38 values in a normal female control population and in a total of 73 normal subjects, including an additional 35 men. We conducted a confirmatory analysis by estimating a mixed linear model with a random effect for subjects. To render the distributions more nearly normal, we transformed the data to the log scale before analysis. We conducted analyses in R (R Foundation for Statistical Computing) and SAS (SAS Institute, Inc.).
Institutional review board approval
The institutional review board at the University of Virginia was consulted to determine if the studies on this one patient required institutional review board approval and a signed consent form. The response (document available on request) indicated that this involved only one patient being evaluated and that this did not require a signed informed consent. Full discussion of the studies with the patient was advised and was accomplished and documented.
Results
Patient presentation
A 46-year-old white female was referred to our Endocrine Unit (University of Virginia) for evaluation of adrenal insufficiency because of persistently low plasma cortisol levels. Major symptoms included weight gain, fatigue, headache, abdominal pain, nausea, diarrhea, excessive urination, muscle and joint aches, and anxiety/ depression. Family history indicated that the patient had 11 Figure 2 . A classification characterizing the degrees of hypersensitivity to glucocorticoids is shown and the key components of each category listed at the bottom. This is a newly devised classification designed to differentiate the degree of hypersensitivity.
siblings, 6 of whom died at childbirth of unknown causes. The patient reported that the remainder who survived complained of similar symptoms but, when contacted, none agreed to be evaluated. The patient is married and has three presumably normal children who have not been examined. Physical examination revealed a blood pressure of 156/82 mm Hg but no other apparent abnormalities. Pertinent laboratory data collected before and during our initial evaluation, recorded in Table 1 
Evaluation of cause of low cortisol levels
Extensive evaluation to reveal the cause of low plasma cortisol levels excluded several possibilities: spurious radioimmunoassay results by comparison with mass spectrometry assays; unreported exogenous glucocorticoid administration with two separate urinary mass spectrometry assays designed to detect exogenous glucocorticoids (Supplemental Table 1 ); corticosteroid-binding protein deficiencies [i.e., corticosteroid-binding globulin (CBG) and albumin]; decreased dexamethasone and hydrocortisone metabolism by dexamethasone blood levels and low cortisol levels, respectively; and primary adrenal insufficiency by a Cortrosyn test (Table 1) . Based on clinical judgment suggesting possible secondary adrenal insufficiency, an empiric, therapeutic trial of glucocorticoid replacement was initiated with 30 mg of hydrocortisone by mouth daily initially, with rapid tapering to 15 mg/d and, finally, to a subreplacement dose of cortisone acetate (15 mg/d). Over 7 months of therapy, the patient developed cushingoid features (weight gain of 18 pounds, exacerbation of hypertension, and facial puffiness) and thus discontinued this therapy. An insulin tolerance test then ruled out ACTH deficiency ( Table 1) .
Verification of low plasma cortisol levels
Because both primary and secondary adrenal insufficiency were ruled out with Cortrosyn and insulin tolerance tests; Table 1 ), we considered it necessary to further validate that the morning cortisol levels were indeed low. Measurement of morning salivary cortisol levels over a 6-week period provided incontrovertible evidence. Twenty-two morning samples of salivary cortisol (Fig. 3A) demonstrated a mean concentration of cortisol of 0.16 6 0.14 mg/dL [SI units, 4.3 6 3.8 nmol/L (mean 6 SD)]. Of these levels, 17/22 were below the lower limit of the morning reference range of the salivary cortisol assay (0.17 to 1.16 mg/dL). The mean of these values was low when compared with the mean of a single morning salivary cortisol measurement in 73 healthy controls [0.53 6 0.25 mg/dL, P = 0.0055 (SI units, 14.7 6 6.9 nmol/L)] and 38 normal female controls [0.54 6 0.25 mg/dL (SI units, 14.9 6 6.9 nmol/L), P , 0.0001]. This result was confirmed in a mixed model analysis (P , 0.0001). In addition, mean morning serum cortisol levels over a 30-month period 
Formal demonstration of glucocorticoid hypersensitivity
These findings, taken together, suggested the possibility of glucocorticoid hypersensitivity. The classical method to demonstrate glucocorticoid hypersensitivity involves an ultra-low-dose dexamethasone (i.e., 0.25 mg) suppression test in conjunction with dexamethasone levels as used previously in patients with hypersensitivity with the GR variants Bcl1 and N363S (2, 22) . As shown in Fig. 3B , 0.25 mg dexamethasone suppressed the patient's morning cortisol to a greater extent than in normal, healthy subjects and to a similar degree as previously reported in patients with Bcl1 and N363S variants (2). Measurement of comparable dexamethasone blood levels as in previous studies served to validate the procedure by excluding reduced dexamethasone metabolism.
GR sequencing
Two variants of GRb were found: GR9b A3669G (heterozygous) and GR9b G3134T (homozygous) but no GRa exon mutations. These two variants are in the 3 0 UTR.
Reductionist approach to determining functionality of mutations
To specifically examine the effect of the various receptors without other confounding influences (reductionist approach), we transfected receptors into osteosarcoma cells devoid of GR and constructed three cell types containing (1) GRa alone; (2) GRa combined with wild-type GRb (GRa/ GRb); and (3) GRa combined with the two separate (A3669G and G3134T) GRb variants, termed GRa/GRb2X. Western blots and immunofluorescent studies demonstrated that the receptor proteins were expressed (Fig.  4A) . As expected from previous reports, hydrocortisone translocated GRa from the cytosol to the nucleus (8) (Fig. 4B) . In contrast, the GRa/ GRb and GRa/GRb2X constructs resided constitutively in the nucleus.
Candidate gene functionality
As an assessment of functionality, we used a candidate gene approach and selected two genes known to be stimulated by glucocorticoids, GILZ and FKBP5. Preliminary studies examined responses to 0.1 to 100 nmol/L hydrocortisone and at 1, 3, and 6 hours with 100 nmol/L hydrocortisone and indicated that the peak effects occurred at 6 hours (data not shown). This concentration and time were then used for subsequent response studies. As shown in Fig. 4C , the response to hydrocortisone was statistically significantly higher in the cells expressing GRa/GRb2X than in the wild-type GRa/GRb with respect to GILZ and trended higher with response to FKBP5. These responses were considered evidence of hypersensitivity.
Global assessment of gene regulation
Using a cDNA array expression system, we compared the three different stably expressing cell lines, each with a unique receptor isoform construct. As shown in the Venn diagram, hydrocortisone altered 2561 genes (i.e., both stimulated and repressed) in the cells expressing GRa only (Fig. 5A) . As evidence of the dominant-negative function of GRb, the construct containing the wildtype GRa/GRb isoforms responded to hydrocortisone with an alteration of only 976 genes. In the mutated cells (GRa/GRb2X), hydrocortisone altered 1852 genes (Fig. 5A) .
We then differentiated responses into stimulation and repression. Of the genes uniquely regulated in the GRa/ GRb wild-type cells, 94% of the genes were stimulated by hydrocortisone and 6% were repressed (313 and 19 genes, respectively), whereas in cells containing the GRa/ GRb2X variants, 79% of the uniquely regulated genes were stimulated, with 21% of the genes repressed (956 and 252 genes, respectively) (Fig. 5B) . In addition, we identified 88 genes that were stimulated 1.5-fold higher (range, 1.5-to 4.5-fold) in the GRa/GRb2x cells than in the wild-type (GRa/GRb). In contrast, only 14 genes were stimulated 1.5-fold higher in the wild-type cells than in the cells with the GRb variants (Fig. 5B) . These results provided further support that the GRa/GRb2X cells were hypersensitive to hydrocortisone.
As another means of illustrating the global gene expression data, we used volcano plots. As shown by the areas enclosed in the blue circles, there were many more genes repressed in the cells containing the Grb variants than in the wild-type (Fig. 5C ).
Functional changes
The complex nature of the gene changes provided a challenge to determine the functional changes because so many different pathways may be involved. In an attempt to evaluate this, we conducted an IPA (Fig. 5D) , which showed that several top canonical 
Studies of candidate genes in the patient's cells
We reasoned that additional alterations of other factors could influence responses in the patient's own cells. In marked contrast, the osteosarcoma cell experiments represented a reductionist approach in which only the variant genes were different. Accordingly, we obtained the patient's white blood cells and examined responsiveness to hydrocortisone in them after separation on a flow cytometry cell sorter. All of her cells contained GR as assessed with an antibody recognizing both GRa and GRb (Supplemental Fig. 1 ). These cells also trended to be hypersensitive to hydrocortisone with respect to the candidate genes, GILZ and FKBP5, supporting observations in the osteosarcoma cells (Fig. 6) .
Substantial literature reported during the 13-year period of our studies indicated that mutations of introns might also be important regulators of hormone actions. Pursuing this recently, we examined the nucleotide 693 base pairs downstream from exon 2 and detected the Bcl1 single nucleotide polymorphism (heterozygous) previously reported as associated with hypersensitivity (1). Although we were unable to examine this in the osteosarcoma cells because it is an intronic mutation, this mutation would likely contribute to glucocorticoid sensitivity in our patient.
Discussion
GR mutations can induce the clinical manifestations of both resistance and hypersensitivity in patients (1-3) . The syndrome of GR resistance (termed Chrousos syndrome) results from several mutations of GRa; its clinical and molecular characteristics have been extensively reported (21, 36) . Examples of patients with mild or moderate degrees of hypersensitivity to glucocorticoids have also been reported, conditions generally resulting from GRa activating mutations. The patient presented in this manuscript presented with GRb variants associated with severe glucocorticoid hypersensitivity as defined by our newly devised classification (Fig. 2) . Mechanistically, the severe degree of hypersensitivity appeared to result from two variants of the dominantnegative GRb as well as an activating mutation of GRa.
All three of the graded clinical features suggesting severe hypersensitivity were present in our patient (Fig.  2) ; molecular studies provided additional support for this conclusion. Clinically, basal cortisol levels were low in the face of normal responsiveness to Cortrosyn and insulin-induced hypoglycemia. The enhanced sensitivity to glucocorticoids reduced her basal cortisol levels, presumably from a reset of the hypothalamic-pituitary feedback axis to cortisol. Further clinical evidence of hypersensitivity emanated from the development of weight gain and cushingoid facial features in response to replacement doses of hydrocortisone and subreplacement amounts of cortisone acetate. More direct evidence of hypersensitivity was provided by results of the ultra-low-dose dexamethasone suppression test with suppressed morning cortisol levels (Fig. 3) . Reductionist molecular studies demonstrated hypersensitivity to hydrocortisone in osteosarcoma cells in which the wild type GRa and the variant GRb receptors were stably transfected. Study of the patient's own cells demonstrated a trend toward hypersensitivity of the candidate genes GILZ and FKBP5.
The pathophysiology in our patient, interestingly, is the converse of that in New World Monkeys (37-39) who have profound glucocorticoid resistance. The levels of plasma cortisol in these monkeys are 7-to 20-fold elevated over normal without cushingoid features and cortisol suppression with dexamethasone is substantially blunted. In contrast, our patient has low plasma cortisol levels, cushingoid features in response to subclinical doses of glucocorticoid, and enhanced suppression of cortisol with dexamethasone.
Our patient presented with severe glucocorticoid hypersensitivity resulting from GR variants. It is likely that the degree of severity, resulting in suppressed cortisol levels, resulted from the combined effects of the GRb and GRa variants. Only one other patient convincingly meeting the clinical criteria for severe glucocorticoid hypersensitivity has been reported, but receptor sequencing was not carried out in that case (40, 41) . Exogenous glucocorticoid use was ruled out by a radioreceptor assay for glucocorticoids. Of interest is that four brothers and three sisters of this previously reported patient died in childhood, a finding similar to that in the patient reported here. Other reported cases of severe glucocorticoid hypersensitivity have been reported but lack of assessment of surreptitious glucocorticoid administration rendered the conclusions nondefinitive (36, (42) (43) (44) (45) (46) . Two previous, well-characterized mutations of GRa, Bcl1, and N363S have been associated with moderate glucocorticoid hypersensitivity as manifested Figure 6 . Regulation of glucocorticoid-responsive genes GILZ and FKBP5 in the patient. RNA was isolated from two separate monocyte preparations from the patient's whole blood cells and treated ex vivo with 100 nmol/L hydrocortisone (HC) for 6 hours. An age-, sex-, and race-matched monocyte preparation was treated at the same time as the patient's cells and used as the control. GILZ and FKBP5 levels were measured using quantitative reverse transcription PCR. Analysis of GR mRNA levels (NR3C1) from the patient and matching control demonstrates the fold levels of each in response to vehicle or HC.
by exaggerated suppression of cortisol induced by ultralow-dose dexamethasone in the face of normal basal cortisol levels.
The symptomatic ramifications of the receptors variants in our patient will remain unclear until additional patients are described. However, IPA suggests that her symptoms could result from alterations of a number of physiological pathways (Fig. 5D) . Because GR are found in multiple tissues, it is possible that her specific complaints might have resulted from differential regulation of the GR in various tissues (7) .
Because severe glucocorticoid hypersensitivity is difficult to suspect clinically, the reported case provides some insight when to suspect this condition. The finding of persistently low plasma cortisol levels in the face of normal testing for primary and secondary adrenal insufficiency would provide the rationale for a high suspicion. Use of the ultra-low-dose dexamethasone suppression test would then confirm hypersensitivity and genetic testing might then be warranted.
The frequency of the GRb variants found in this patient has previously been studied in 3730 patients of diverse backgrounds (32) . The G3134T variant was present at a frequency of 50.7% for one copy and 23.3% for two copies and the A3669G variant in 1.66% for two copies and 18.7% for one copy. In a smaller study, the A3669G variant was found in normal blood donors with no disease in nine patients (47) . The relative frequencies of the known GRa variants associated with moderate hypersensitivity (i.e., 6% for N363S and 14% for Bcl1) and the frequencies of the GRb variants reported above suggest that the syndrome of severe glucocorticoid hypersensitivity may not be exceedingly rare.
This study, although extensive, has limitations. The ultra-low-dose dexamethasone suppression test evaluated morning cortisol levels only and not delta responses. A full assessment of the reported case remains to be carried out. Future studies include full cDNA array analysis of the patient's own mononuclear cells, CRISPR/ CAS 9 correction of the mutations in the patient's cells, and comparison of glucocorticoid responsiveness in the cells containing wild-type vs GRa and GRb receptors. Clinical candidate and population studies will be required to identify other patients with severe glucocorticoid hypersensitivity.
In summary, this article reports a case of severe glucocorticoid hypersensitivity in a patient resulting from GR variants. In this patient, variants of the dominantnegative GRb were associated with the glucocorticoid hypersensitivity, likely amplified by the Bcl-1 mutation of GRa. This prismatic case provides key insights into the interactions between the activating GRa receptor and its dominant-negative GRb partner.
